EDITORIAL
Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression?
Claudia P. Oliveira,
Corresponding Author
Claudia P. Oliveira
Department of Gastroenterology, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Correspondence
Claudia P. Oliveira, Department of Gastroenterology, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Email: [email protected]
Search for more papers by this author
Claudia P. Oliveira,
Corresponding Author
Claudia P. Oliveira
Department of Gastroenterology, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Correspondence
Claudia P. Oliveira, Department of Gastroenterology, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Email: [email protected]
Search for more papers by this author
First published: 05 April 2022
No abstract is available for this article.
CONFLICT OF INTEREST
Nothing to report.
REFERENCES
- 1Walker RW, Belbin GM, Sorokin EP, Van Vleck T, Wojcik GL, Moscati A, et al. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. J Hepatol. 2020 Mar 5:S0168-8278(20)30123-9.
- 2Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, et al.; EPoS Consortium Investigators. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol. 2020; 73(3): 505–15.
- 3Vilar-Gomez E, Pirola CJ, Sookoian S, Wilson LA, Liang T, Chalasani N. PNPLA3 rs738409 and risk of fibrosis in NAFLD: exploring mediation pathways through intermediate histological features. Hepatology. 2022; 76:1482–94.
- 4Lindén D, Ahnmark A, Pingitore P, Ciociola E, Ahlstedt I, Andréasson AC, et al. PNPLA3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in PNPLA3 I148M knock-in mice. Mol Metab. 2019 Apr; 22: 49–61.
- 5Banini BA, Kumar DP, Cazanave S, Seneshaw M, Mirshahi F, Santhekadur PK, et al. Identification of a metabolic, transcriptomic, and molecular signature of patatin-like phospholipase domain containing 3–mediated acceleration of steatohepatitis. Hepatology. 2021 Apr; 73(4): 1290–306.
- 6Arrese M, Arab JP, Riquelme A, Benitez M, Barrera F, Soza A, et al. High prevalence of PNPLA3 rs738409 (I148M) polymorphism in Chilean Latino population and its association to nonalcoholic fatty liver disease risk and histological disease severity. Hepatology. 2015; 62:1285A.
- 7Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res. 2009; 50(10): 2111–6.
- 8Mazo DF, Malta FM, Stefano JT, Salles APM, Gomes-Gouvea MS, Nastri ACS, et al. Validation of PNPLA3 polymorphisms as risk factors for NAFLD and liver fibrosis in an admixed population. Ann Hepatol. 2019 May-Jun; 18(3): 466–71.
- 9Machado CM, Leite NC, França PH, Cardoso CR, Salles GF, Villela-Nogueira CA. PNPLA3 gene polymorphism in Brazilian patients with type 2 diabetes: a prognostic marker beyond liver disease? Nutr Metab Cardiovasc Dis. 2019 Sep; 29(9): 965–71.
